Clinical Trial Update: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis [Phase 1]

View source ↗

Summary

This first-in-human, single ascending-dose Phase 1 trial of GZ402668 in patients with progressive multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• GZ402668 (GZ402668)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Progressive Multiple Sclerosis | Phase 1 | Status: COMPLETED